Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and organ protection of urate-lowering drugs in gout/hyperuricemia
ChiCTR2000035778Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in gout and hyperuricemia comparing Allopurinol group, Febuxostat group and Benzbromarone group (3 arms). Primary endpoints: Major Adverse Cardiovascular Events and Chinese cardiovascular and cerebrovascular assessment. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
allopurinolfebuxostatbenzbromarone
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on ChiCTR2000035778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035778.